 Multiple Sclerosis
"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 6 | 0 | 6 | | 1998 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 2 | 4 | 6 | | 2003 | 8 | 0 | 8 | | 2004 | 4 | 1 | 5 | | 2005 | 16 | 0 | 16 | | 2006 | 11 | 2 | 13 | | 2007 | 13 | 1 | 14 | | 2008 | 13 | 1 | 14 | | 2009 | 15 | 0 | 15 | | 2010 | 13 | 1 | 14 | | 2011 | 14 | 2 | 16 | | 2012 | 13 | 2 | 15 | | 2013 | 8 | 3 | 11 | | 2014 | 12 | 0 | 12 | | 2015 | 10 | 0 | 10 | | 2016 | 12 | 3 | 15 | | 2017 | 13 | 2 | 15 | | 2018 | 20 | 0 | 20 | | 2019 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Clifford DB, Tyler KL. Dosing interval of natalizumab in MS: Do good things come to those who wait? Neurology. 2019 10 08; 93(15):655-656.
-
Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun; 25(3):715-735.
-
Rhead B, Shao X, Graves JS, Chitnis T, Waldman AT, Lotze T, Schreiner T, Belman A, Krupp L, Greenberg BM, Weinstock-Guttman B, Aaen G, Tillema JM, Rodriguez M, Hart J, Caillier S, Ness J, Harris Y, Rubin J, Candee MS, Gorman M, Benson L, Mar S, Kahn I, Rose J, Casper TC, Quach H, Quach D, Schaefer C, Waubant E, Barcellos LF. miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. Ann Clin Transl Neurol. 2019 Jun; 6(6):1053-1061.
-
Leon MA, Wemlinger SM, Larson NR, Ruffalo JK, Sestak JO, Middaugh CR, Cambier JC, Berkland C. Soluble Antigen Arrays for Selective Desensitization of Insulin-Reactive B Cells. Mol Pharm. 2019 04 01; 16(4):1563-1572.
-
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):845-854.
-
Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019 03 05; 92(10):e1016-e1028.
-
Chi C, Shao X, Rhead B, Gonzales E, Smith JB, Xiang AH, Graves J, Waldman A, Lotze T, Schreiner T, Weinstock-Guttman B, Aaen G, Tillema JM, Ness J, Candee M, Krupp L, Gorman M, Benson L, Chitnis T, Mar S, Belman A, Casper TC, Rose J, Moodley M, Rensel M, Rodriguez M, Greenberg B, Kahn L, Rubin J, Schaefer C, Waubant E, Langer-Gould A, Barcellos LF. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808.
-
Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262.
-
Mañago MM, Hebert JR, Kittelson J, Schenkman M. Feasibility of a targeted strengthening program to improve gait in people with multiple sclerosis: a brief report. Int J Rehabil Res. 2018 Dec; 41(4):364-367.
-
Weinkle L, Domen CH, Shelton I, Sillau S, Nair K, Alvarez E. Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal. Mult Scler Relat Disord. 2019 Jan; 27:383-390.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|